Mitsubishi UFJ Trust & Banking Corp Sells 13,075 Shares of STERIS plc $STE

Mitsubishi UFJ Trust & Banking Corp lowered its position in shares of STERIS plc (NYSE:STE) by 24.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 40,782 shares of the medical equipment provider’s stock after selling 13,075 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in STERIS were worth $10,339,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of STERIS by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 12,286,535 shares of the medical equipment provider’s stock worth $3,114,882,000 after purchasing an additional 73,014 shares during the period. State Street Corp grew its position in STERIS by 4.0% during the third quarter. State Street Corp now owns 4,354,839 shares of the medical equipment provider’s stock worth $1,077,564,000 after buying an additional 166,736 shares in the last quarter. Orbis Allan Gray Ltd grew its position in STERIS by 36.0% during the second quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock worth $504,486,000 after buying an additional 556,088 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in STERIS by 16.4% during the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,567,238 shares of the medical equipment provider’s stock worth $387,797,000 after buying an additional 221,199 shares in the last quarter. Finally, Invesco Ltd. grew its position in STERIS by 4.9% during the third quarter. Invesco Ltd. now owns 1,280,142 shares of the medical equipment provider’s stock worth $316,758,000 after buying an additional 59,443 shares in the last quarter. Institutional investors own 94.69% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on STE. Weiss Ratings downgraded STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, April 16th. Wall Street Zen downgraded STERIS from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 26th. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, STERIS currently has an average rating of “Moderate Buy” and a consensus target price of $275.20.

Insider Buying and Selling at STERIS

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the firm’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total value of $734,876.58. Following the sale, the director owned 705 shares of the company’s stock, valued at approximately $167,233.05. This trade represents a 81.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.07% of the company’s stock.

STERIS Trading Down 1.0%

Shares of NYSE:STE opened at $214.78 on Friday. The company has a market capitalization of $21.06 billion, a P/E ratio of 29.96 and a beta of 0.95. STERIS plc has a 1 year low of $209.98 and a 1 year high of $269.44. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.48 and a quick ratio of 1.75. The business’s 50 day simple moving average is $226.36 and its 200 day simple moving average is $244.69.

STERIS (NYSE:STE) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The firm’s revenue for the quarter was up 9.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.32 EPS. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, research analysts anticipate that STERIS plc will post 10.22 EPS for the current fiscal year.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.